Flagship progresses deal with Pfizer into obesity

Flagship Pioneering and its founded company ProFound Therapeutics today announced a collaboration to conduct foundational research to identify potential next-generation first-in-class therapies for the treatment of obesity.

The collaboration is the first initiated under Flagship's Pioneering Medicines strategic partnership with US pharma giant Pfizer (NYSE: OFE) announced in July last year, under which Flagship and its bioplatform companies are eligible to receive up to $700 million in milestones and royalties for each successfully commercialized program.

Pioneering Medicines, Flagship's in house drug discovery and development unit, is responsible for leading the partnership with Pfizer, including driving the exploration process to rapidly surface potential drug development programs built on Flagship's diverse bioplatforms and modalities.